- Home
- CUE vs FNWB Comparison
CUE vs FNWB Comparison
Compare CUE & FNWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- FNWB
- Stock Information
- Founded
- CUE 2014
- FNWB 1923
- Country
- CUE United States
- FNWB United States
- Employees
- CUE N/A
- FNWB N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- FNWB Banks
- Sector
- CUE Health Care
- FNWB Finance
- Exchange
- CUE Nasdaq
- FNWB Nasdaq
- Market Cap
- CUE 91.9M
- FNWB 95.2M
- IPO Year
- CUE 2018
- FNWB 2015
- Fundamental
- Price
- CUE $1.26
- FNWB $10.88
- Analyst Decision
- CUE Strong Buy
- FNWB Hold
- Analyst Count
- CUE 5
- FNWB 1
- Target Price
- CUE $5.00
- FNWB $12.00
- AVG Volume (30 Days)
- CUE 285.6K
- FNWB 16.1K
- Earning Date
- CUE 03-10-2025
- FNWB 01-29-2025
- Dividend Yield
- CUE N/A
- FNWB 2.59%
- EPS Growth
- CUE N/A
- FNWB N/A
- EPS
- CUE N/A
- FNWB N/A
- Revenue
- CUE $9,532,000.00
- FNWB $50,900,000.00
- Revenue This Year
- CUE $73.11
- FNWB N/A
- Revenue Next Year
- CUE $11.02
- FNWB $11.60
- P/E Ratio
- CUE N/A
- FNWB N/A
- Revenue Growth
- CUE 149.53
- FNWB N/A
- 52 Week Low
- CUE $0.45
- FNWB $8.91
- 52 Week High
- CUE $2.45
- FNWB $16.00
- Technical
- Relative Strength Index (RSI)
- CUE 45.93
- FNWB 56.99
- Support Level
- CUE $1.20
- FNWB $10.70
- Resistance Level
- CUE $1.50
- FNWB $11.10
- Average True Range (ATR)
- CUE 0.12
- FNWB 0.22
- MACD
- CUE -0.02
- FNWB 0.01
- Stochastic Oscillator
- CUE 16.67
- FNWB 63.33
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.